Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

(+)-Catechin in a 1:2 Complex with Lysine Inhibits Cancer Cell Migration and Metastatic Take in Mice.

Payen VL, Porporato PE, Danhier P, Vazeille T, Blackman MCNM, May BH, Niebes P, Sonveaux P.

Front Pharmacol. 2017 Dec 4;8:869. doi: 10.3389/fphar.2017.00869. eCollection 2017.

2.

Alpha-Tocopherol prevents esophageal squamous cell carcinoma by modulating PPARγ-Akt signaling pathway at the early stage of carcinogenesis.

Xu M, Yang H, Zhang Q, Lu P, Feng Y, Geng X, Zhang L, Jia X.

Oncotarget. 2017 Sep 30;8(56):95914-95930. doi: 10.18632/oncotarget.21437. eCollection 2017 Nov 10.

3.

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Eshraghian A.

World J Gastroenterol. 2017 Nov 14;23(42):7495-7504. doi: 10.3748/wjg.v23.i42.7495.

4.

Oxidative stress and prostatic diseases.

Roumeguère T, Sfeir J, El Rassy E, Albisinni S, Van Antwerpen P, Boudjeltia KZ, Farès N, Kattan J, Aoun F.

Mol Clin Oncol. 2017 Nov;7(5):723-728. doi: 10.3892/mco.2017.1413. Epub 2017 Sep 19.

5.

Organoids model distinct Vitamin E effects at different stages of prostate cancer evolution.

Njoroge RN, Unno K, Zhao JC, Naseem AF, Anker JF, McGee WA, Nonn L, Abdulkadir SA.

Sci Rep. 2017 Nov 24;7(1):16285. doi: 10.1038/s41598-017-16459-2.

6.

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.

Kosaka T, Hongo H, Miyazaki Y, Nishimoto K, Miyajima A, Oya M.

Oncotarget. 2017 Sep 21;8(50):87675-87683. doi: 10.18632/oncotarget.21147. eCollection 2017 Oct 20.

7.

Natural Forms of Vitamin E as Effective Agents for Cancer Prevention and Therapy.

Jiang Q.

Adv Nutr. 2017 Nov 15;8(6):850-867. doi: 10.3945/an.117.016329. Print 2017 Nov. Review.

PMID:
29141970
8.

The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications.

Dal S, Sigrist S.

Diseases. 2016 Jul 11;4(3). pii: E24. doi: 10.3390/diseases4030024. Review.

9.

Vitamin K and its analogs: Potential avenues for prostate cancer management.

Dasari S, Ali SM, Zheng G, Chen A, Dontaraju VS, Bosland MC, Kajdacsy-Balla A, Munirathinam G.

Oncotarget. 2017 May 19;8(34):57782-57799. doi: 10.18632/oncotarget.17997. eCollection 2017 Aug 22. Review.

10.

Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.

Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG.

J Diabetes Complications. 2017 Nov;31(11):1630-1637. doi: 10.1016/j.jdiacomp.2017.07.014. Epub 2017 Jul 31. Review.

PMID:
28886991
11.

Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats.

Zhu W, Chen S, Chen R, Peng Z, Wan J, Wu B.

BMC Complement Altern Med. 2017 Sep 8;17(1):455. doi: 10.1186/s12906-017-1961-3.

12.

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Greuter T, Malhi H, Gores GJ, Shah VH.

JCI Insight. 2017 Sep 7;2(17). pii: 95354. doi: 10.1172/jci.insight.95354. [Epub ahead of print] Review.

13.

Procyanidin B2 3,3″-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.

Kumar R, Deep G, Wempe MF, Surek J, Kumar A, Agarwal R, Agarwal C.

Mol Carcinog. 2018 Jan;57(1):57-69. doi: 10.1002/mc.22731. Epub 2017 Sep 22.

PMID:
28876465
14.

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study.

Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, Tomeno W, Imajo K, Fujita K, Yoneda M, Kataoka K, Taguri M, Yamanaka T, Seko Y, Tanaka S, Saito S, Ono M, Oeda S, Eguchi Y, Aoi W, Sato K, Itoh Y, Nakajima A.

BMC Gastroenterol. 2017 Aug 8;17(1):96. doi: 10.1186/s12876-017-0652-3.

15.

Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches.

Leone A, Roca MS, Ciardiello C, Costantini S, Budillon A.

Oxid Med Cell Longev. 2017;2017:2597581. doi: 10.1155/2017/2597581. Epub 2017 Jul 9. Review.

16.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

PMID:
28754796
17.

New Challenges to Study Heterogeneity in Cancer Redox Metabolism.

Benfeitas R, Uhlen M, Nielsen J, Mardinoglu A.

Front Cell Dev Biol. 2017 Jul 11;5:65. doi: 10.3389/fcell.2017.00065. eCollection 2017. Review.

18.

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.

Portillo-Sanchez P, Cusi K.

Clin Diabetes Endocrinol. 2016 Apr 12;2:9. doi: 10.1186/s40842-016-0027-7. eCollection 2016. Review.

19.

Vitamin E and Alzheimer's Disease-Is It Time for Personalized Medicine?

Cervantes B, Ulatowski LM.

Antioxidants (Basel). 2017 Jun 24;6(3). pii: E45. doi: 10.3390/antiox6030045. Review.

20.

Non-alcoholic fatty liver disease: An expanded review.

Benedict M, Zhang X.

World J Hepatol. 2017 Jun 8;9(16):715-732. doi: 10.4254/wjh.v9.i16.715. Review.

Supplemental Content

Support Center